Dunn MW, Kazer MW. Prostate cancer overview. Semin Oncol Nurs. 2011;27(4):241–50.

Rawla P. Epidemiology of Prostate Cancer. World J Oncol. 2019;10(2):63–89.

Hussain AM, Lafta RK. Cancer trends in Iraq 2000–2016. Oman Medical Journal. 2021;36(1):e219.

Khoshnaw N, Mohammed HA, Abdullah DA. Patterns of Cancer in Kurdistan - Results of Eight Years Cancer Registration in Sulaymaniyah Province-Kurdistan-Iraq. Asian Pac J Cancer Prev. 2015;16(18):8525–31.

Mahadevan GS, Arunachalam VK, Rajasekaran S, Kashyap R, Gunasekaran K, Thirumoorthi S. Anatomy of the Prostate Gland: Modalities and Techniques for Its Assessment. Journal of Gastrointestinal and Abdominal Radiology. 2024;7(2).

Barrett KE, Barman SM, Yuan JX. Ganong’s review of medical physiology (-2019): McGraw-Hill Education Medical; 2019.

Pierorazio PM, Walsh PC, Partin AW, Epstein JI. Prognostic G leason grade grouping: data based on the modified G leason scoring system. BJU International. 2013;111(5):753–60.

Engers R. Reproducibility and reliability of tumor grading in urological neoplasms. World Journal of Urology. 2007;25:595–605.

Melia J, Moseley R, Ball R, Griffiths D, Grigor K, Harnden P, et al. A UK‐based investigation of inter‐and intra‐observer reproducibility of Gleason grading of prostatic biopsies. Histopathology. 2006;48(6):644–54.

Richardsen E, Andersen S, Al-Saad S, Rakaee M, Nordby Y, Pedersen MI, et al. Evaluation of the proliferation marker Ki-67 in a large prostatectomy cohort. PloS One. 2017;12(11):e0186852.

Sulik M, Maruszak K, Puchalska J, Misiukiewicz-Poć M. Expression of Ki-67 as a proliferation marker in prostate cancer. Polish Annals of Medicine. 2011;18(1):12–9.

MA, Moradi G, Zareie B, Sofimajidpour H, Tozandehjani S, Zafari H, et al. Overall survival and prognostic factors prostate cancer in Kurdistan Province-Iran: a population-based study (2011–2018). BMC Cancer. 2021;21(1):1314.

Onal C, Guler OC, Elmali A, Demirhan B, Yavuz M. The impact of age on clinicopathological features and treatment results in patients with localised prostate cancer receiving definitive radiotherapy. Acta Oncol. 2024;63:858–66.

Aseafan M, Devol E, AlAhwal M, Souissi R, Sindi R, AlEid H, Bazarbashi S. Population-based survival for cancer patients in Saudi Arabia for the years 2005–2009. Sci Rep. 2022;12(1):235.

Xu H, Zhang LM, Liu J, Ding GX, Ding Q, Jiang HW. The association between overall survival of prostate cancer patients and hypertension, hyperglycemia, and overweight in Southern China: a prospective cohort study. J Cancer Res Clin Oncol. 2013;139(6):943–51.

Park EH, Jung KW, Park NJ, Kang MJ, Yun EH, Kim HJ, et al. Cancer Statistics in Korea: Incidence, Mortality, Survival, and Prevalence in 2021. Cancer Res Treat. 2024;56(2):357–71.

Aaltomaa S, Lipponen P, Vesalainen S, Ala-Opas M, Eskelinen M, Syrjänen K. Value of Ki-67 immunolabelling as a prognostic factor in prostate cancer. European Urology. 1997;32(4):410–5.

Aaltomaa S, Kärjä V, Lipponen P, Isotalo T, Kankkunen J, Talja M, Mokka R. Expression of Ki-67, cyclin D1 and apoptosis markers correlated with survival in prostate cancer patients treated by radical prostatectomy. Anticancer Research. 2006;26(6C):4873–8.

Li R, Heydon K, Hammond ME, Grignon DJ, Roach III M, Wolkov HB, et al. Ki-67 staining index predicts distant metastasis and survival in locally advanced prostate cancer treated with radiotherapy: an analysis of patients in radiation therapy oncology group protocol 86–10. Clinical Cancer Research. 2004;10(12):4118–24.

Siddiqui S. Assessment of Ki-67 expression in cases of prostatic carcinoma and its correlation with clinical outcomes. Indian J Pathol Microbiol.

;67(2):362–6.

Rasheed, E. A. (2016). Diagnostic Role of Some Immunohistochemical markes in prostatic pathology (Doctoral dissertation, Ministry of higher Education).

Wu R, Hu M, Zhang P. Predictive value of systematic immune-inflammation index combined with Ki-67 index on prognosis of prostate cancer patients after laparoscopic radical prostatectomy. BMC Urol. 2023;23(1):210.

Rubio J, Ramos D, López-Guerrero JA, Iborra I, Collado A, Solsona E, et al. Immunohistochemical expression of Ki-67 antigen, cox-2 and Bax/Bcl-2 in prostate cancer; prognostic value in biopsies and radical prostatectomy specimens. Eur Urol. 2005;48(5):745–51.

Yılmaz MB, Salim Başol Tekin. Survival Analysis and Prognostic Factors in Prostate Cancer Patients: A Single Center Experience in Eastern Anatolia. Dicle Medical Journal. 2020;47(4):796–805.

Alasker A, Arabi TZ, Alghafees MA, Sabbah BN, Abdul Rab S, Alageel AK, et al. Prostate cancer among Saudis: a registry review. Ann Med Surg (Lond). 2024;86(1):56–61.

Song Z, Zhou Q, Zhang JL, Ouyang J, Zhang ZY. Marker Ki-67 is a potential biomarker for the diagnosis and prognosis of prostate cancer based on two cohorts. World J Clin Cases. 2024;12(1):32–41.

Sepahvand M, Salehi A, Omidvari A, Omidvari S, Mohammadianpanah M. Prostate Cancer Survival Analysis of 872 Patients in Southern Iran: A Retrospective Cohort Study. Middle East Journal of Cancer. 2023;14(4):570–7.

Khor LY, Bae K, Paulus R, Al-Saleem T, Hammond ME, Grignon DJ, et al. MDM2 and Ki-67 predict for distant metastasis and mortality in men treated with radiotherapy and androgen deprivation for prostate cancer: RTOG 92-02. J Clin Oncol. 2009;27(19):3177–84.

Berney DM, Gopalan A, Kudahetti S, Fisher G, Ambroisine L, Foster CS, et al. Ki-67 and outcome in clinically localised prostate cancer: analysis of conservatively treated prostate cancer patients from the Trans-Atlantic Prostate Group study. Br J Cancer. 2009;100(6):888–93.

Abdelbary EH, Hegazy AA, Abdelgawad M, Ahmed RA. Role of ERG, PTEN and KI67 proteins expression in prognosis of metastatic prostate cancer. International Journal of Advanced Research. 2015;3(1):296–306.